US 8,466,139 B2 | Formulation

Please sign up or log in to access the advanced features of
Ex Parte Enterprise.

or Log in

General

US 8,466,139 B2

Formulation

Tech Center:

1600 Biotechnology and Organic Chemistry

Examiner:

San-Ming Hui

Art Unit:

1629 Organic Chemistry

Agent:

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Inventors:

John R. Evans; Rosalind U. Grundy

Assignee:

ASTRAZENECA

Priority:

01/10/00

Filed:

09/04/12

Granted:

06/18/13

Expiration:

07/21/25

Abstract

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.

General

Analytics

Cases

Patent Assignments

Citations